Financings in Brief: FemRx
This article was originally published in The Gray Sheet
Executive Summary
FemRx: Gynecological device company plans to go public with an initial offering of 2.7 mil. shares of common stock at $11 to $13 each. Proceeds would go towards sales and marketing, R&D, and "other general corporate purposes, including working capital," the firm states. Sunnyvale, California-based FemRx's initial products are the Opera Star outpatient endometrial resection/ablation specialized tissue aspirating resectoscope for use to "cut, coagulate and aspirate tissue within the uterus," and the Flo-Stat fluid management system for gynecologic procedures. Robertson, Stephens & Co. and Dillon Read & Co. are managing the offering...